资讯

Checkpoint Inhibitors Competitive Landscape & Pipeline 2025: Emerging Therapies, Leading ...

On 28 August 2025, AstraZeneca conducted a Phase IIIb NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA ...